AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 87 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,536,253 | +55.3% | 3,410,106 | 0.0% | 0.01% | +80.0% |
Q1 2023 | $988,931 | -35.5% | 3,410,106 | 0.0% | 0.01% | -44.4% |
Q4 2022 | $1,534,207 | -14.5% | 3,410,106 | 0.0% | 0.01% | -25.0% |
Q3 2022 | $1,794,000 | +4.2% | 3,410,106 | 0.0% | 0.01% | +20.0% |
Q2 2022 | $1,722,000 | -78.0% | 3,410,106 | 0.0% | 0.01% | -77.8% |
Q1 2022 | $7,843,000 | -51.6% | 3,410,106 | 0.0% | 0.04% | -43.0% |
Q4 2021 | $16,198,000 | -40.3% | 3,410,106 | 0.0% | 0.08% | -33.6% |
Q3 2021 | $27,110,000 | +14.2% | 3,410,106 | 0.0% | 0.12% | +14.4% |
Q2 2021 | $23,734,000 | -12.1% | 3,410,106 | 0.0% | 0.10% | -11.1% |
Q1 2021 | $27,008,000 | +0.6% | 3,410,106 | 0.0% | 0.12% | +15.8% |
Q4 2020 | $26,838,000 | -13.6% | 3,410,106 | -22.1% | 0.10% | -18.5% |
Q3 2020 | $31,051,000 | -23.4% | 4,379,592 | 0.0% | 0.12% | -30.7% |
Q2 2020 | $40,511,000 | +407.3% | 4,379,592 | +155.6% | 0.18% | +265.3% |
Q1 2020 | $7,985,000 | -39.0% | 1,713,604 | 0.0% | 0.05% | -30.0% |
Q4 2019 | $13,092,000 | -0.7% | 1,713,604 | 0.0% | 0.07% | -22.2% |
Q3 2019 | $13,178,000 | +12.3% | 1,713,604 | 0.0% | 0.09% | +12.5% |
Q2 2019 | $11,738,000 | -14.9% | 1,713,604 | 0.0% | 0.08% | -9.1% |
Q1 2019 | $13,795,000 | +7.5% | 1,713,604 | 0.0% | 0.09% | -16.2% |
Q4 2018 | $12,835,000 | -3.4% | 1,713,604 | +23.5% | 0.10% | +20.7% |
Q3 2018 | $13,282,000 | -9.5% | 1,387,872 | 0.0% | 0.09% | -20.9% |
Q2 2018 | $14,684,000 | +30.1% | 1,387,872 | +22.0% | 0.11% | +14.6% |
Q1 2018 | $11,288,000 | +83.4% | 1,137,872 | 0.0% | 0.10% | +81.1% |
Q4 2017 | $6,156,000 | +9.8% | 1,137,872 | 0.0% | 0.05% | +17.8% |
Q3 2017 | $5,609,000 | +28.0% | 1,137,872 | 0.0% | 0.04% | +18.4% |
Q2 2017 | $4,381,000 | +209.6% | 1,137,872 | +498.9% | 0.04% | +216.7% |
Q1 2017 | $1,415,000 | -19.5% | 189,987 | -53.0% | 0.01% | -29.4% |
Q4 2016 | $1,758,000 | -32.1% | 404,230 | 0.0% | 0.02% | -29.2% |
Q3 2016 | $2,591,000 | +31.9% | 404,230 | 0.0% | 0.02% | +14.3% |
Q2 2016 | $1,965,000 | – | 404,230 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $532,000 | 6.17% |
Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |